jasmone: RN refers to (Z)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 1549018 |
CHEMBL ID | 2251602 |
CHEBI ID | 6084 |
SCHEMBL ID | 20385 |
Synonym |
---|
3-methyl-2-[(z)-pent-2-enyl]cyclopent-2-en-1-one |
2-cyclopenten-1-one, 3-methyl-2-(2-pentenyl)-, (z)- |
einecs 207-668-4 |
brn 1907713 |
fema no. 3196 |
LMFA02020009 |
3-methyl-2-(pent-2z-enyl)cyclopent-2-enone |
2-cyclopenten-1-one, 3-methyl-2-[(2z)-2-pentenyl]- |
3-methyl-2-(2-cis-pentenyl)-2-cyclopenten-1-one |
3-methyl-2-n-penten-2'-ylcyclopenten-2-one |
(z)-jasmone |
3-methyl-2-(2-pentenyl)-2-cyclopenten-1-one |
2-cyclopenten-1-one, 3-methyl-2-(2-pentenyl)-, (z)- (8ci) |
3-methyl-2-(cis-2-penten-1-yl)-2-cyclopenten-1-one |
cmc_7381 |
3-methyl-2-(2-pentenyl)-2-cyclopenten-1-one, (z)- |
cis-3-methyl-2-(2-pentenyl)-2-cyclopenten-1-one |
3-methyl-2-(cis-2-pentenyl)-2-cyclopenten-1-one |
3-methyl-2-pent-2-enylcyclopent-2-enone |
jasmone (6ci) |
2-cyclopenten-1-one, 3-methyl-2-(2z)-2-pentenyl- (9ci) |
jasmone |
488-10-8 |
cis-jasmone |
C08490 |
cis-jasmone, stabilized |
jasmone, 90% |
cis-jasmon |
J0003 |
dtxcid2027092 |
dtxsid4047092 , |
tox21_301825 |
NCGC00256139-01 |
cas-488-10-8 |
AKOS024318891 |
3-methyl-2-[(z)-pent-2-enyl]-cyclopent-2-en-1-one |
unii-rc4w0g9yuk |
4-07-00-00337 (beilstein handbook reference) |
2-cyclopenten-1-one, 3-methyl-2-(2z)-2-penten-1-yl- |
hsdb 8273 |
rc4w0g9yuk , |
S4960 |
(z)-3-methyl-2-(pent-2-en-1-yl)cyclopent-2-enone |
SCHEMBL20385 |
CHEMBL2251602 |
chebi:6084 , |
methyl-2-(2-pentenyl)-2-cyclopenten-1-one, (z)-, 3- |
jasmone [fhfi] |
jasmone [mi] |
3-methyl-2-[(2z)-2-pentenyl]-2-cyclopenten-1-one # |
GS-3251 |
3-methyl-2-[(2z)-pent-2-en-1-yl]cyclopent-2-en-1-one |
cis-3-methyl-2-pent-2-enyl-cyclopent-2-enone |
jasmone, analytical standard |
3-methyl-2-[(2z)-2-pentenyl]-2-cyclopenten-1-one |
(z)-3-methyl-2-(2-pentenyl)-2-cyclopenten-1-one |
BCP18948 |
HY-N7058 |
Q418077 |
cis-?jasmone |
CCG-266315 |
AC7789 |
CS-W017899 |
2-cyclopenten-1-one, 3-methyl-2-(2z)-2- pentenyl- |
EN300-7400412 |
Cis-Jasmone (CJ) is a plant-derived chemical that enhances direct and indirect plant defence against herbivorous insects. It acts as an attractant for pollinators and as a chemical cue for host localisation (or avoidance) for insects. Cis-jasmone is a highly appreciated fragrance and plant- derived signal molecule.
Excerpt | Reference | Relevance |
---|---|---|
"cis-Jasmone (CJ) is a natural plant product that activates defence against herbivores in model and crop plants. " | ( Priming of Production in Maize of Volatile Organic Defence Compounds by the Natural Plant Activator cis-Jasmone. Birkett, MA; Bruce, TJ; Caulfield, JC; Dewhirst, SY; Oluwafemi, S; Pickett, JA; Powers, S; Veyrat, N, 2013) | 1.16 |
"cis-jasmone (CJ) is a plant-derived chemical that enhances direct and indirect plant defence against herbivorous insects. " | ( The transcriptome of cis-jasmone-induced resistance in Arabidopsis thaliana and its role in indirect defence. Bruce, TJ; Matthes, MC; Napier, JA; Pickett, JA; Ton, J; Verrier, PJ, 2010) | 1.22 |
"cis-Jasmone is a volatile organic compound emitted constitutively by flowers or leaves of several plant species where it acts as an attractant for pollinators and as a chemical cue for host localisation (or avoidance) for insects. " | ( Emerging roles in plant defense for cis-jasmone-induced cytochrome P450 CYP81D11. Bruce, T; Chamberlain, K; Matthes, M; Napier, J; Pickett, J, 2011) | 1.19 |
"cis-Jasmone is a member of the fragrance structural group ketones cyclopentanones and cyclopentenones." | ( Fragrance material review on cis-jasmone. Api, AM; Jones, L; Letizia, CS; Scognamiglio, J, 2012) | 1.14 |
"cis-Jasmone is a plant volatile known to have roles as an insect semiochemical and in inducing plant defence. " | ( cis-Jasmone treatment induces resistance in wheat plants against the grain aphid, Sitobion avenae (Fabricius) (Homoptera: Aphididae). Bruce, TJ; Martin, JL; Pickett, JA; Pye, BJ; Smart, LE; Wadhams, LJ, 2003) | 1.44 |
"cis-Jasmone is known to be a plant activator in terms of production of defence-related volatile semiochemicals that repel aphids and increase the foraging activity of aphid parasitoids." | ( cis-Jasmone induces accumulation of defence compounds in wheat, Triticum aestivum. Birkett, MA; Bromilow, R; Gordon-Weeks, R; Martin, JL; Moraes, MC; Pickett, JA; Pye, BJ; Smart, LE, 2008) | 1.38 |
"Cis-jasmone is a highly appreciated fragrance and plant-derived signal molecule that controls pollination, attracts parasitoids of attacking herbivores, and serves as an intra- and interspecific signal that controls gene expression. " | ( Iso-OPDA: an early precursor of cis-jasmone in plants? Boland, W; Dabrowska, P, 2007) | 1.17 |
Excerpt | Reference | Relevance |
---|---|---|
"Jasmone has no effect on the E1<-->E2 equilibrium constant for the ATPase or on Ca2+ binding." | ( Mechanism of stimulation of the calcium adenosinetriphosphatase by jasmone. East, JM; Hughes, G; Lee, AG; Starling, AP, 1994) | 1.25 |
Excerpt | Relevance | Reference |
---|---|---|
" Our electrophysiological results show a dose-response relationship between the EAG amplitudes and the increasing concentrations of the olfactory compound." | ( Association between olfactory sensitivity and behavioral responses of Drosophila suzukii to naturally occurring volatile compounds. Corda, G; Crnjar, R; Delogu, G; Dettori, MA; Fabbri, D; Solari, P; Sollai, G, 2020) | 0.56 |
" The dose-response analysis confirmed an allosteric type of AhR antagonism." | ( Jasmone Is a Ligand-Selective Allosteric Antagonist of Aryl Hydrocarbon Receptor (AhR). Dvořák, Z; Krasulová, K; Marcalíková, A; Vrzal, R; Zemánková, L, 2023) | 2.35 |
Class | Description |
---|---|
cyclic ketone | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
AR protein | Homo sapiens (human) | Potency | 68.5896 | 0.0002 | 21.2231 | 8,912.5098 | AID743042 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 38.5708 | 0.0010 | 22.6508 | 76.6163 | AID1224838 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 68.5896 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 34.3762 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 54.9410 | 0.0002 | 29.3054 | 16,493.5996 | AID743069 |
nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 38.5708 | 0.0006 | 27.2152 | 1,122.0200 | AID743219 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
AID1090712 | Thrips luring activity against male New Zealand Thrips obscuratus (flower thrips) assessed as ratio of thrips in baited traps to unbaited traps during field trapping study | 2007 | Journal of agricultural and food chemistry, Jul-25, Volume: 55, Issue:15 | 4-pyridyl carbonyl and related compounds as thrips lures: effectiveness for onion thrips and new zealand flower thrips in field experiments. |
AID1090713 | Thrips luring activity against female New Zealand Thrips obscuratus (flower thrips) assessed as ratio of thrips in baited traps to unbaited traps during field trapping study | 2007 | Journal of agricultural and food chemistry, Jul-25, Volume: 55, Issue:15 | 4-pyridyl carbonyl and related compounds as thrips lures: effectiveness for onion thrips and new zealand flower thrips in field experiments. |
AID1090711 | Thrips luring activity against female Thrips tabaci (onion thrips) assessed as ratio of thrips in baited traps to unbaited traps during field trapping study | 2007 | Journal of agricultural and food chemistry, Jul-25, Volume: 55, Issue:15 | 4-pyridyl carbonyl and related compounds as thrips lures: effectiveness for onion thrips and new zealand flower thrips in field experiments. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 4 (6.90) | 18.2507 |
2000's | 19 (32.76) | 29.6817 |
2010's | 26 (44.83) | 24.3611 |
2020's | 9 (15.52) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (46.76) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 5 (8.33%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 55 (91.67%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |